NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization9.37 mln
Float3.97 mln
Earnings Date08/19/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.07
Highly suspicious
Relative Strength
94
/ 100
Top performer
Debt / Equity
0.07
Debt-free
ROE
-53.74
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
CytoMed Therapeutics is a Singapore-based biopharmaceutical company founded in 2018 that develops cell-based treatments for cancer and degenerative diseases across Malaysia and Singapore. Its pipeline includes several advanced therapy candidates that use the body's own immune cells ? such as gamma delta T cells and stem cells ? to target and destroy a wide range of cancers, as well as an injectable stem cell product designed to treat cartilage injuries. The company's lead cancer treatment is currently in Phase I clinical trials, and CytoMed works alongside hospital and research partners in Singapore to advance its therapies toward broader clinical use.
